Iovance Biotherapeutics Inc. (NASDAQ:IOVA) price on Thursday, August 26, rose 0.42% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $23.67.
A look at the stock’s price movement, the level at last check in today’s session was $23.57, moving within a range at $22.45 and $23.84. The beta value (5-Year monthly) was 0.85. Turning to its 52-week performance, $54.21 and $15.88 were the 52-week high and 52-week low respectively. Overall, IOVA moved 7.97% over the past month.
Iovance Biotherapeutics Inc.’s market cap currently stands at around $3.51 billion, with investors looking forward to this quarter’s earnings report slated for Nov 03, 2021 – Nov 08, 2021. Analysts project the company’s earnings per share (EPS) to be -$0.51, which has seen fiscal year 2021 EPS growth forecast to increase to -$2.1 and about -$2.26 for fiscal year 2022. Per the data, EPS growth is expected to be -11.70% for 2021 and -7.60% for the next financial year.
Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was no upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that IOVA is a 50% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
14 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 3 analyst(s) rate the stock as a Hold, 9 recommend IOVA as a Buy and 2 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Overweight which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
IOVA’s current price about 5.72% and -0.14% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 56.78, while 7-day volatility ratio is 5.38% and 5.00% in the 30-day chart. Further, Iovance Biotherapeutics Inc. (IOVA) has a beta value of 0.86, and an average true range (ATR) of 1.13. Analysts have given the company’s stock an average 52-week price target of $40.31, forecast between a low of $18.00 and high of $86.00. Looking at the price targets, the low is 23.95% off recent price level in today’s trading while to achieve the yearly target high, it has to move -263.33%. Nonetheless, investors will most likely welcome a -60.54% jump to $38.00 which is the analysts’ median price.
In the market, a comparison of Iovance Biotherapeutics Inc. (IOVA) and its peers suggest the former has performed considerably stronger. Data shows IOVA’s intraday price has changed 0.42% today and -17.41% over the past year. Comparatively, Expeditors International of Washington Inc. (EXPD) has moved -1.21% so far today and only 41.96% in the past 12 months. Looking at another peer, we see that Hub Group Inc. (HUBG) price has dipped -0.99% on the day. However, the stock is 25.18% off its price today a year ago. Moreover, Forward Air Corporation (FWRD) is also down -1.31% in today’s trading while keeping a an uptrend of 49.55% over the past year. Elsewhere, the overall performance for the S&P 500 and Dow Jones Industrial shows that the indexes are down -0.33% and -0.14% respectively on the day as seen in early trades.
If we refocus on Iovance Biotherapeutics Inc. (NASDAQ:IOVA), historical trading data shows that trading volumes averaged 2.23 million over the past 3 months. The company’s latest data on shares outstanding shows there are 153.75 million shares.
The 0.62% of Iovance Biotherapeutics Inc.’s shares are in the hands of company insiders. Current price change has pushed the stock -49.20% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the IOVA stock continues to rise going into the next quarter.